Dante Carrillo
Diet pills have long been marketed as a quick and easy solution to weight loss, but their history is marred by health risks and even fatalities. The removal of diet pills from the market is often a result of their adverse effects, which range from insomnia and anxiety to severe cases of heart valve problems, high blood pressure, and even cancer. The decision to withdraw these pills is typically made by regulatory bodies such as the Food and Drug Administration (FDA) in the United States, which has taken action against popular non-prescription and prescription diet pills, including those containing phenylpropanolamine, sibutramine, and amphetamines.
| Characteristics | Values |
|---|---|
| Date | October 2010 |
| Company | Abbott Laboratories Inc |
| Product | Meridia or sibutramine |
| Reason | Linked to high blood pressure and a risk of heart attack and stroke in cardiovascular patients |
| Other | Approved in November 1997 |
| Other Products Withdrawn | Diatec Diet Aid Drops, Dietic tablets, Ayds AM/PM, Appetite Suppressant Capsules, Control Drops, Extra Strength Appedrine tablets, Vita-Slim Capsules, Super Odrinex Tablets, Power-Slim Packets and Bio Slim T Time-Release Capsules |
| Drug | Phenylpropanolamine |
| Side Effects | Unimpressive weight loss, potentially dangerous side effects, and sudden attacks of very high blood pressure |
| Other | The drug was deemed "safe and effective" by an FDA panel |
Explore related products
What You'll Learn
- Fenfluramine, part of the fen-phen drug combination, was withdrawn from the market in 1997
- Abbott Laboratories Inc pulls Meridia or sibutramine from the U.S. market in 2010
- Diet pills containing phenylpropanolamine were withdrawn from the market due to dangerous side effects
- The FDA rejected Qnexa, a diet pill made by Vivus Inc, in 2010 over heart risk concerns
- Fenproporex-based diet pills imported from Brazil have been linked to adverse effects such as insomnia, anxiety, palpitations, fatigue and nausea/vomiting
Fenfluramine, part of the fen-phen drug combination, was withdrawn from the market in 1997
Fenfluramine, an appetite suppressant used to treat obesity, was withdrawn from the US market in 1997 due to its association with cardiovascular toxicity. It was sold under the brand name Pondimin and in combination with phentermine, commonly known as fen-phen. Fen-phen was an anti-obesity medication that was heavily marketed and sold in the early 1990s.
The decision to withdraw fenfluramine was made after reports of valvular heart disease and pulmonary hypertension, primarily in women undergoing treatment with fen-phen. The FDA received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. This disease typically involves the aortic and mitral valves. The distinctive valvular abnormality seen with fenfluramine is a thickening of the leaflet and chordae tendineae. This may have been caused by the stimulation of heart valve serotonin receptors, as fenfluramine and its active metabolite norfenfluramine are known to stimulate these receptors.
In 1995, Wyeth introduced dexfenfluramine (Redux), which was intended to cause fewer adverse effects. However, the medical officer of the FDA, Leo Lutwak, insisted on a black box warning of pulmonary hypertension risks. After Lutwak refused to approve the drug, it was approved for marketing in 1996 without the black box warning. In 1996, a 30-year-old woman developed heart problems after using fen-phen for a month and died in February 1997. This led to further scrutiny of the drug combination.
Fenfluramine was first introduced for medical use as an appetite suppressant in France in 1963 and was approved in the United States in 1973. It was developed in the early 1960s and acts as a serotonin and norepinephrine releasing agent. While fenfluramine has been withdrawn from the market as a weight-loss drug, it has since been repurposed for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. It was approved for medical use in the United States for this indication in 2020.
Vegetarian Diets: Why Do They Cause Bloating?
You may want to see also
Explore related products
Abbott Laboratories Inc pulls Meridia or sibutramine from the U.S. market in 2010
Abbott Laboratories Inc. voluntarily withdrew Meridia (sibutramine) from the U.S. market in October 2010. The diet drug was initially approved by the Food and Drug Administration (FDA) in November 1997 for weight loss and weight loss maintenance in obese people and certain overweight individuals at risk of heart disease.
Meridia was pulled from the market due to concerns about its cardiovascular risks. A clinical trial involving over 10,000 patients found that 11.4% of participants who took the drug experienced a heart attack, stroke, or other major cardiac problems, compared to 10% of those taking a placebo. This represented a 16% increase in relative risk.
Despite Abbott's assertion that the drug was safe for appropriate patients, the company complied with the FDA's request to withdraw Meridia from the market. The decision was welcomed by consumer groups, although some argued that it was long overdue and had put patients at risk.
The withdrawal of Meridia dealt a blow to efforts to develop safe medications for treating obesity, a significant health problem in the United States.
Metformin and Diet: What You Should Eat
You may want to see also
Explore related products
Diet pills containing phenylpropanolamine were withdrawn from the market due to dangerous side effects
Diet pills have long been a popular way to lose weight, but they have also been associated with a number of health risks. In the 1980s, the Food and Drug Administration (FDA) in the United States asked companies to take their best-selling diet pills off the market due to concerns about dangerous side effects. The pills in question contained the drug phenylpropanolamine, which can cause sudden attacks of very high blood pressure and is dangerous for anyone with heart disease or diabetes.
The products being withdrawn included Diatec Diet Aid Drops, Dietic tablets, Ayds AM/PM, Appetite Suppressant Capsules, Control Drops, Extra Strength Appedrine tablets, Vita-Slim Capsules, Super Odrinex Tablets, Power-Slim Packets, and Bio Slim T Time-Release Capsules. Some companies were quick to comply with the FDA's request, while others did not initially respond.
Phenylpropanolamine was once thought to be safe and effective as a diet aid, with some studies showing that dieters taking the drug lost an average of one pound a week, compared to half a pound a week for those on a placebo. However, this finding has been criticized by other experts, who argue that there is no good evidence that phenylpropanolamine or any other drug can help obese patients achieve long-term weight reduction. Furthermore, the drug's performance was questioned, with some suggesting that it simply gives people the impression that they can lose weight by taking a pill, rather than through lifestyle changes.
The withdrawal of diet pills containing phenylpropanolamine is not an isolated incident. Throughout history, several weight-loss drugs have been pulled from the market due to health risks. For example, in 1997, fenfluramine, part of the "fen-phen" drug combination, was withdrawn due to heart valve problems. More recently, in 2010, Abbott Laboratories Inc pulled Meridia or sibutramine from the U.S. market due to high blood pressure and an increased risk of heart attack and stroke in cardiovascular patients. In the same year, the FDA rejected two other diet pills, lorcaserin and Qnexa, due to concerns about cancer risk and heart risks, respectively.
Tonic Water and Fasting: Breaking the Fast?
You may want to see also
Explore related products
The FDA rejected Qnexa, a diet pill made by Vivus Inc, in 2010 over heart risk concerns
In October 2010, the FDA rejected Qnexa, a weight-loss drug developed by Vivus Inc. This decision was based on concerns regarding heart risks and other issues, with the FDA requesting further data and studies to assess these risks. Qnexa is a combination of two drugs: phentermine, an appetite-suppressing stimulant, and topiramate, an anti-seizure medication that also affects appetite. While clinical trials showed that Qnexa was effective in helping obese and overweight patients lose weight, with some panelists deeming it "far superior to anything on the market", the potential for psychiatric and cardiovascular issues outweighed the benefits.
The FDA expressed specific concerns about the elevation in heart rate and the potential for birth defects if taken during pregnancy. In response, Vivus stated that they would provide new analyses to address these concerns and asserted their confidence in the safety and efficacy of Qnexa. This rejection was not unexpected, as an advisory committee to the FDA had previously voted 10-6 against approval, citing similar worries.
The Qnexa case highlights the challenges in developing safe and effective weight-loss treatments, particularly in a market where obesity is a significant issue. It also underscores the importance of rigorous evaluation by regulatory bodies like the FDA to ensure that the benefits of a drug outweigh the risks. This event serves as a reminder that even with promising clinical trial results, further studies and data may be necessary to address safety concerns and ultimately gain approval for widespread use.
Explore the Staple Dishes of the Mediterranean Diet
You may want to see also
Explore related products
Fenproporex-based diet pills imported from Brazil have been linked to adverse effects such as insomnia, anxiety, palpitations, fatigue and nausea/vomiting
Diet pills have a long and troubled history, with many being withdrawn from the market due to dangerous side effects. For example, in the 1960s, "rainbow pills", a combination of amphetamine, digitalis, and diuretics, were linked to several deaths. More recently, in 2010, Abbott Laboratories Inc pulled Meridia (sibutramine) from the U.S. market due to warnings about high blood pressure and an increased risk of heart attack and stroke in cardiovascular patients.
Fenproporex-based diet pills imported from Brazil have also been linked to adverse effects and health risks. Fenproporex was initially developed to suppress appetite without causing stimulant effects. However, it has since been found to have addictive potential and is rapidly converted into amphetamine in the body. The United Nations has warned that the overprescribing of amphetamine-based anorectics in South America could contribute to their international distribution.
In Brazil, prescriptions for compounded diet pills are typically obtained from physicians in private practice who market themselves as obesity experts. These pills often contain three to six prescription medications, including amphetamines, benzodiazepines, antidepressants, diuretics, thyroid hormones, laxatives, and other substances. None of these medications are indicated for the treatment of obesity according to commonly accepted practice guidelines.
A study found that two-thirds of diet pill users experienced side effects, with insomnia, anxiety, palpitations, fatigue, and nausea/vomiting being the most common. Additionally, case reports from the United States and Spain have described severe abdominal pain, hyperthyroidism, hypokalemia, and syncope associated with the use of these compounded diet pills. Urine toxicology screens have detected amphetamines and benzodiazepines in individuals using these diet pills, and symptoms have resolved after discontinuing their use. Given the wide variety of potential adverse effects, physicians should be aware of the composition and dangers of fenproporex-based diet pills imported from Brazil to provide better care for their patients.
Rice and Carnivore Diets: A Good Mix?
You may want to see also
Frequently asked questions
Diet pills have been linked to several health issues, including high blood pressure, heart valve problems, heart attacks, strokes, insomnia, anxiety, palpitations, fatigue, nausea, and vomiting. Some pills have also been found to be addictive.
Fenfluramine, part of the "fen-phen" drug combination, was withdrawn from the market in September 1997 due to heart valve problems.
Other examples include Aminorex, an appetite suppressant taken off the European market in 1971; Meridia or sibutramine, removed from the U.S. market in October 2010; and Acomplia, withdrawn in November 2008.
Imported diet pills, particularly those from Brazil, have been found to contain amphetamines and benzodiazepines, leading to adverse effects such as chest pains, palpitations, headaches, and insomnia.
Unapproved diet pills, such as certain GLP-1 drugs, may not be safe and can be illegally marketed with false information. Counterfeit drugs may contain harmful ingredients or incorrect amounts of active ingredients.
